News

Home / News

Announcement on behalf of major subsidiary, TOP PHARM. MEDICALWARE COMPANY LIMITED, regarding the release of non-competition restrictions for Directors

2025.9.9

1.Date of the shareholders' meeting resolution:2025/09/09

2.Name and title of the managerial officer with permission to engage in competitive conduct:Lai-Shou Su;Director

3.Items of competitive conduct in which the officer is permitted to engage:Similiar scope of business of director of management.

4.Period of permission to engage in the competitive conduct: The period of being director of the Company.

5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):
(1)4,478,283 in total voting rights were represented at the time of voting;
(2)4,478,283 voting right presented for, 100% of total voting rights;
(3)0 voting right presented against, 0% of total voting rights;
(4)0 invalid votes, 0% of total voting rights;
(5)0 voting right presented abstention and not voting,0% of total voting rights;
(6)This proposal was approved as proposed as affirmative rights higher than statutory ones.

6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below):N/A

7.Company name of the mainland China enterprise and the officer’s position in the enterprise:N/A

8.Address of the mainland China enterprise:N/A

9.Operations of the mainland China enterprise:N/A

10.Impact on the company’s finance and business:N/A

11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:N/A

12.Any other matters that need to be specified:None.